Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis and high mortality rate. Inhibitor of differentiation-1 (ID-1) overexpression has already been reported to be associated with low survival, but the detailed roles of ID-1 in PDAC are unclear. As an ID-1 inhibitor, 2-methoxyestradiol (2-ME) has been shown effective in the antitumor therapies, but its effect on PDAC is unknown. In this study, ID-1 overexpression and knockdown stable SW1990 cells were used to examine proliferation, migration and invasion abilities. Effectiveness of 2-ME was estimated in vivo, as well as in vitro by survival analysis, magnetic resonance imaging and tissue analysis. PDAC patients were retrospectively reviewed to assess the ID-1 expression and prognosis. We found that ID-1 was closely associated with in vitro SW1990 cells proliferation, migration and invasion abilities, as well as the expression of HIF-1α, VEGF and MMP-9. 2-ME was shown to be effective on tumor suppression both in vivo and in vitro, perhaps mainly by ID-1 regulation. Moreover, the relevance between high ID-1 expression and poor prognosis was validated in PDAC patients. Our data collectively reveals the roles of ID-1 in PDAC malignancy, and suggests 2-ME treatment may be a potential alternative chemotherapeutic agent for PDAC patients.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and high mortality rate (1) , with an overall 5-year survival rate less than 5% (2, 3) . Radical surgery is the only curative therapy, but many patients present at diagnosis with locally advanced or late stage tumors Patients with metastatic disease have a median survival of only 6 months. Palliative chemotherapies with FOLFIRINOX or nab-Paclitaxel with Gemcitabine are recommended as first line chemotherapy for patients with non-resectable PDAC (4, 5) , but more drugs are urgently needed to improve overall survival and provide new systematic therapeutic options.
Id proteins (inhibitors of differentiation or DNA binding) are members of basic helix-loop-helix (bHLH) transcription factors family. They can form inactive Id-bHLH protein complexes, acting as dominant-negative regulators (6) . ID-1 overexpression has been reported in many types of cancers in either transcriptional or translational levels, including breast, prostate and pancreatic cancers (7) . For PDAC, ID-1was found to be a prognosis factor associated with patients' survival (8, 9) . However, the detailed roles of ID-1 in PDAC are still unknown. 2-Methoxyestradiol (2-ME) is a natural derivative of estradiol. Compared to estradiol, this derivative does not exhibit direct estrogenic activity in vitro or in vivo because of its low binding affinity to estrogen receptor (10) . 2-ME has been shown to reduce proliferation and migration abilities in several tumors, and has been reported to have the ability of suppressing ID-1 level (11, 12) . So it is uncertain that if 2-ME has the effect on restraining PDAC progression.
In the present study, we aimed to demonstrate the role of ID-1 in pancreatic cancer development and progression, by clinical data and in vitro functional verification. Furthermore, we tried to estimate the effect of 2-ME in PDAC cells and in vivo tumor implantation models, searching for potential alternative chemotherapeutic agents for PDAC patients.
Material and methods

Cell line and cell culture
SW1990 cell line, stable LV-ID1-RNAi-SW1990, CON077-SW1990 (control), LV-ID-SW1990 and CON238-SW1990 (control) cells were obtained from GENECHEM (Shanghai, China) on June, 2016. For SW1990 cell line, it has been tested and authenticated just before experiments by short tandem repeat method. Detailed sites, primers and the result were reported in Supplementary Table 1, available at Carcinogenesis Online. For stable LV-ID1-RNAi-SW1990 and LV-ID-SW1990 cells, transfection efficiency was examined before further experiments (Supplementary Figure 1 , available at Carcinogenesis Online). Pancreatic cancer cell lines SW1990 was cultured in RPMI 1640 (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum in the condition of 37°C, 5% CO 2 .
Cell transfection and transduction
All of lentivirus was transfected into indicated cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Virus infection was performed by incubating SW1990 cells with medium containing indicated virus and 8 ug/ml polybrene (Sigma-Aldrich) for 72 h and then selected with 2 μg/ml puromycin (Sigma-Aldrich) for 48 h to establish stable cells. Stable cell lines were confirmed by GFP-labeled positive cells rate and real-time quantitative RT-PCR after selection.
RNA extraction and real-time PCR
Samples from different experiment cell groups were used to extract the total RNA by Trizol reagent (Invitrogen) using 500 ng RNA to reverse transcript to cDNA using the RNA-to-cDNA kit (TaKaRa). And then quantitative real-time PCR (qRT-PCR) reactions were carried out using the SYBR Master Mixture (TaKaRa). The RT products were detected by PCR reaction which denatured for 30 s at 95°C, 5 s for 95°C, 30 s for 60°C by 40 cycles in all. All the data were described using the comparative quantitative threshold cycle (ΔΔCt) method. The primer sequences are ID-1: F: 5′-GTAAACGTGCTGCTCTACGACATGA-3′, R: 5′-AGCTCCAACTGAAGGTCCCTGA-3′; HIF-1α: F: 5′-GTTAGTTCAATTTTGATC CCCTTTCT-3′, R: 5′-GCTACTGCAATGCAATGGTTTAA-3′, GAPDH: F: 5′-TG ACTTCAACAGCGACACCCA-3′, R: 5′-CACCCTGTTGCTGTAGCCAAA-3′; VEGF: F: 5′-ATGACGAGGGCCTGGAGTGTG-3′, R: 5′-CCTATGTGCTGGCCTT GGTGAG-3′; MMP-9: F: 5′-CCTGGAGACCTGAGAACCAATC-3′, R: 5′-CCACC CGAGTGTAACCATAGC-3′. Each experiment was repeated at least three times and representative data are shown.
Immunohistochemistry
Rabbit polyclonal antibodies against VEGF (1:250 dilution; Abcam, Cambridge, UK), MMP-9 (1:100 dilution; Abcam), ID-1 (1:200 dilution; Abcam), p53 (1:100 dilution; Abcam) and HIF-1α (1:200 dilution; Abcam) were used for immunohistochemical staining. The secondary antibody was goat antirabbit immunoglobulin (1:500 dilution; Abcam).
Western blotting
Total proteins extracted from the tissues or cells were subjected to western blot analysis for HIF-1α, ID-1, p53, VEGF, MMP-9 or GAPDH in standard routine with relative antibodies (Santa Cruz Biotechnology). Quantitative analysis was performed by LAS-3000 imaging system (FUJIFILM Inc, Tokyo, Japan).
Cell proliferation assay
SW1990-ID1-NC, SW1990-ID1-OE, SW1990-ID1-KD cells and normal SW1990 cells (cultured with or without 2-ME) were seeded in 96-well plates. For CCK-8 assay, cells were cultured at a density of 3 × 10 3 cells per well, measured using CCK-8 assay (Dojindo, Kumamoto, Japan) for a 2-h incubation period at 37°C and the absorbance rates were read at 450 nm by a microplate reader (Epoch2, BioTek). For MTT (3-[4,5-Dimethylthiazol-2-y1]-2,5-diphenyltetrazolium bromide) assay, cells were seeded into 96-well plates at a density of 2 × 10 3 cells per well allowed to attach for 24 h. Four hours before termination, cells were added 0.5 mg/ml MTT (Genview, Inc) to each well and incubated for 4 h at 37°C. The violet MTT formazan precipitates were subsequently dissolved in 100 μl dimethylsulfoxide (DMSO). The absorbance at 490 nm was measured by a microplate reader (Tecan infinite).
Colony formation assay
For colony formation assays, cells were trypsinized into a single-cell suspension and seeded in six-well plates at 2 × 10 3 per well. After 10 days of incubation, the colonies were stained with crystal violet dye.
Wound-healing assay
For cell motility assay, stably transfected SW1990 cells were seeded in six-well plates to near 70% confluence. A linear wound was carefully made by a 10-μl sterile pipette tip across the confluent cell monolayer. Cell debris was removed by washing with phosphate-buffered saline and incubated with RPMI-1640 medium. The wounded monolayer was then photographed at 0, 24 and 48 h after wounding. Cells were observed under a microscope (×25). The ImageJ software was used to measure the wound width. Wound closure rate was calculated by the present/initial width ratio, demonstrated as wound closure %.
Transwell assay
3 × 10 5 cells were resuspended in 200 μl serum-free medium and plated in the top chamber, while 800 μl medium with 20% fetal bovine serum was added as a chemoattractant in the lower chamber. After 24 h incubation, cells on the lower surface of membrane were stained with crystal violet dye, photographed, and counted under a microscope (DMi8, Leica) in five fields.
In vivo tumorigenicity and metastasis assay
Experimental protocols for animals were approved by the Huashan Hospital Institutional Board, Fudan University, Shanghai, China. Study design was in accordance with the ARRIVE guidelines. Eighty male BALB/c nu/nu mice weighing 20-25 g, aged about 6-8 weeks were used in this study. All mice were bred and kept in an IVC-II room. Mice underwent surgical procedures after intraperitoneal injection of 10% chloral hydrate at a dose of 0.2 ml/100 g and with 1% lidocaine local anesthesia.
1 × 10 7 of SW1990 cells were injected subcutaneously into the right axilla of 6-8-week-old BALB/c nu/nu male mice weight 20-25 g (10 mice each group). All the model mice were randomly assigned into DMSO (400 μl/kg per day) or 2-ME-treated group (100 mg/kg per day, dissolved DMSO as 250 mg/ml), by subcutaneous injection. The tumor sizes were monitored by measuring tumor diameters during sampling 21 days after injection. Both the maximum (length) and minimum (width) of the tumor were measured by a slide caliper, and the tumor volume was calculated by the formula V = 1/2(L × W 2 ). Total RNA and protein were extracted from the tumor tissues of sacrificed mice for further tests.
For liver metastasis model, mice were performed left subcostal incision, 5 mm length. 5 × 10 6 of SW1990 cells were injected via spleen (20 mice each group), needle was kept for 2 min to avoid reflux. Then the spleen was resected from hilus lienis, ligatured blood vessels. All the injected mice were randomly assigned into DMSO (400 μl/kg per day) or 2-ME-treated group (100 mg/kg per day, dissolved DMSO as 250 mg/ml), by intraperitoneal injection. Tumor metastasis was analyzed by MR scan (3.0T SIEMENS, T2-weighed sequence) 2 and 3 weeks after modeling, six Abbreviations ID-1 inhibitor of differentiation-1 2-ME 2-methoxyestradiol DMSO dimethylsulfoxide PDAC pancreatic ductal adenocarcinoma mice for each group. Then all mice were euthanized and the livers were excised for further experiments at the third week. 
Clinical data collection
Statistical analysis
All statistical data were analyzed with GraphPad Prism 5 software. All statistical significance was determined by one-way ANOVA with NewmanKeuls test for post hoc analysis. Multivariate analysis, Chi-square and Fisher's exact test was used for the clinical data. The overall survival analysis using Kaplan-Meier curves were analyzed by log rank test. A P value of < 0.05 was considered statistically significant. All results are presented as mean ± SD.
Results
Down-regulating ID-1 inhibits proliferation, migration, invasion and colony formation of human SW1990 cell lines
First, to estimate the role of ID-1 in SW1990 cells, we determined the proliferation ability of LV-ID1-RNAi-SW1990 cells (ID-1-) by clone formation ( Figure 1A ). Transfection efficiency was examined before further experiments (Supplementary Figure 1A , available at Carcinogenesis Online). After ID-1 knockdown, LV-ID1-RNAi-SW1990 cells showed lower proliferation ability than CON077-SW1990 cells (control, P = 0.0095, Figure 1B ). MTT assay also confirmed the decreased proliferation ability of LV-ID1-RNAi-SW1990 cells from days 1 to 5 ( Figure 1C ). Next, we examined cell migration and invasion by using wound healing assays Matrigel-coated transwell ( Figure 1D and E). By ID-1 knockdown, migration ability was obviously suppressed on 8 and 24 h compared with controls ( Figure 1F , P < 0.001). Furthermore, downregulating ID-1 again attenuated invasion rate of SW1990 cells significantly ( Figure 1G , P < 0.001).
Upregulating ID-1 increases proliferation, migration, invasion and colony formation of human SW1990 cell lines
Then, we examined the proliferation ability of LV-ID-SW1990 cells (ID-1+) by clone formation (Figure 2A ). Transfection efficiency was examined before further experiments (Supplementary Figure 1B , available at Carcinogenesis Online). After ID-1 overexpression, LV-ID-SW1990 cells showed higher proliferation ability than CON238-SW1990 cells (control, P < 0.001, Figure 2B ). MTT assay also confirmed the increased proliferation ability of LV-ID1-SW1990 cells from days 1 to 5, but showed no significance ( Figure 2C , P = 0.06). Next, we examined cell migration and invasion ability. In LV-ID-SW1990 cells ( Figure 2D and E). Wound closure rates were obviously elevated on 8 and 24 h compared to controls ( Figure 2F , P < 0.001), as well as the cell invasion rate by using Matrigel-coated transwell ( Figure 2G , P < 0.001).
2-ME suppresses ID-1 expressions in several human pancreatic cancer cell lines and inhibits SW1990 cells proliferation
Up to now, we have already confirmed the role of ID-1 in SW1990 cells proliferation, migration and invasion abilities. Then we tried to examine the effect of 2-ME on ID-1 expressions in other human pancreatic cancer cell lines ( Figure 3A) . By 2-ME intervention, ID-1 levels in BXPC-3, Capan-1/2, GV254, Panc-1 and SW1990 cells were all suppressed to various extent, and demonstrated dose-effect relationship at the concentration of 5, 10 and 20 mM compared to DMSO-treated cells after 48 h (Figure 3B-G) . Furthermore, we also examined the effect of 2-ME on SW1990 cells proliferation. CCK-8 assay showed that 2-ME intervention could inhibit SW1990 proliferation ability significantly either at 10 or 20 mM compared to DMSO ( Figure 3H , P < 0.001), after 72 h culture.
2-ME suppresses SW1990 cells proliferation, migration, invasion relaying on ID-1
To estimate the mechanism of the 2-ME on in vitro antitumor effect, we respectively examine the proliferation, migration, invasion of LV-ID1-RNAi-SW1990 with or without 2-ME culture. By ID-1 knockdown, 2-ME can no longer suppress the SW1990 cells proliferation, migration and invasion more obviously than ID-1 knockdown alone (Supplementary Figure 2 , available at Carcinogenesis Online). Besides, LV-ID1-RNAi-SW1990 cells has a lower invasion rate than normal SW1990 cultured by 2-ME (20 mM) (P < 0.05, Supplementary Figure 2C and D, available at Carcinogenesis Online), as well as the MTT assay on the days 2 and 3 (P < 0.001, Supplementary Figure 2E , available at Carcinogenesis Online). Those results indicate that ID-1 regulation may be the mechanism of 2-ME antitumor effect in vitro.
2-ME treatment inhibits tumor growth in BALB/c nu/ nu mice
To investigate the antitumor effect of 2-ME in vivo, we subcutaneously transplanted SW1990 cells in BALB/c nud/nud mice, followed by 2-ME or DMSO injection in situ as described in Materials and Methods ( Figure 4A ). After 3 weeks daily 2-ME treatment, we can observe a reduced of tumor size in contrast with DMSOtreated mice ( Figure 4B , P < 0.01). Histopathologically, all subcutaneous tumors were composed of PDAC cells ( Figure 4C ). Immunochemical staining showed ID-1 positive cells were significantly less in the tumor after 2-ME intervention ( Figure 4D ). Western blot also revealed the level of ID-1 was down-regulated (P < 0.05, Figure 4E and F), as well as the levels of HIF-1α, VEGF and MMP-9 (P < 0.05, Figure 4G -J).
Down-regulating ID-1 suppress the expression of HIF-1α, VEGF and MMP-9
To further estimate the mechanism of the 2-ME on suppressing HIF-1α, VEGF and MMP-9, we examined the expression level of those factors in LV-ID1-RNAi-SW1990, CON077 and normal SW1990 cells (Supplementary Figure 3 , available at Carcinogenesis Online). We found that HIF-1α, VEGF and MMP-9 were all decreased in LV-ID1-RNAi-SW1990 compared to CON077 cells (P < 0.001, P < 0.001 and P < 0.05, Supplementary Figure 3C -E, available at Carcinogenesis Online), as well as VEGF and MMP-9 mRNA levels (P < 0.001, Supplementary Figure 3F and G, available at Carcinogenesis Online) However, mRNA of HIF-1α in LV-ID1-RNAi-SW1990 was not significantly suppressed (Supplementary Figure 3H , available at Carcinogenesis Online). Those results indicated that ID-1 down-regulation by 2-ME is the main reason for HIF-1α, VEGF and MMP-9 suppression.
2-ME treatment prolongs overall survival in SW1990 cells liver metastasis model but not inhibits liver metastasis
In addition, we performed a survival study in BALB/c nu/nu mice SW1990 liver metastasis model. Mice were assigned randomly to each group and intraperitoneally injected by 2-ME or DMSO, lasting for 3 weeks as explained in Materials and methods. All mice were showed liver metastasis by magnetic resonance imaging scan at the third week (6/6 in each group, Figure 5A ), and metastasis tumors were composed of PDAC cells ( Figure 5B ). Overall, 2-ME-treated mice improved survival compared to DMSO by Kaplan-Meier analysis (P = 0.0349, Figure 5C ). Immunochemical staining and western bolt demonstrated that ID-1 level in the metastasis tumor was suppressed by 2-ME intervention (P < 0.001), as well as the HIF-1α (P < 0.05, Figure 5D and E). However, 2-ME treatment did not inhibit early metastasis at the second week by magnetic resonance imaging scan (4/6 versus 0/6, Supplementary Figure 4 , available at Carcinogenesis Online).
ID-1 levels in the PDAC is correlated with prognosis in patients without lymphatic metastasis
Finally, we investigated whether ID-1 protein is correlated with prognosis in PDAC patients. Ninety-four patients were finally enrolled into this study, with the medium follow-up time of 12 months (3-58 months). Among the enrolled patients, the positive intensity of ID-1 was various. Immunochemical staining indicated ID-1 could be overexpressed and located either in the nucleus or the cytoplasm in PDAC tissue but not in normal pancreatic tissues ( Figure 6A ). In pancreatic cancer tissues, the positive expression rate of ID-1 was 94.68%. The scores among ID-1 positive patients included low score (11.24%), medium score (29.21%) and high score (59.55%). Patients' characters were demonstrated in Supplementary Table 2 , available at Carcinogenesis Online. Elevated ID-1 expression in pancreatic cancer tissue was strongly correlated with tumor histological differentiation in (P = 0.046) and gender (P = 0.035), showed in Supplementary  Table 3 , available at Carcinogenesis Online. However, ID-1 had no statistical criteria with age, tumor size, location, lymphovascular invasion or TNM stage. We then determined the role ID-1 played in survival. The Kaplan-Meier analysis for all the PDAC patients revealed no differences in survival by Log-rank test ( Figure 6B ), as well as in T2 and T3 stage patients (Supplementary Figure 5 , available at Carcinogenesis Online). That is mainly because of the cross of the three survival curves. However, it is obvious that after 18 months, either low or medium score patients have a survival advantage than the high score patients, especially for the low score patients. In addition, in stage N0 PDAC patients, Kaplan-Meier analysis demonstrated that patients with medium ID-1 score have a better survival rate than patients with high score (P = 0.0383, Figure 6C ). But in the N1 stage PDAC patients, Kaplan-Meier analysis showed no correlations between ID-1 score and survival rate ( Figure 6D ). Collectively, all the results suggest that ID-1 maybe a biomarker for the prognosis of PDAC patients.
Discussion
This study has firstly revealed the importance of ID-1 in PDAC cells' behaviors. As a transcription regulation factor, ID-1 overexpression can increase the proliferation, migration and invasion abilities of SW1990 cells. On the other hand, in the stable LV-ID1-RNAi-SW1990 cells, those abilities were remarkably suppressed. The knowledge of ID-1 protein is mainly from oncology researches. ID-1 is a member of the ID protein family, proved to regulate cell differentiation, cell-cycle progression and apoptosis (13) . Kim et al. (14) found the possibility of cross talk between ID-1 and HIF-1α, either from normoxic or hypoxic conditions. ID-1 can enhance HIF-1α protein stability, nuclear translocation, and transcriptional activity in breast cancer cells. Although ID-1 is strongly implicated in tumor angiogenesis, and ID-1 overexpression is reported in numerous cancer cells, there are few reports showing the detailed role of ID-1 in PDAC.
In our study, we found that down-regulating ID-1 could suppress the expression of HIF-1α, MMP-9 and VEGF in SW1990 cells. The mechanism by which ID-1 enhances tumor invasion involves a variety of mechanisms. Among these mechanisms, ID-1 induces the expression of MMPs. In melanoma (15) and breast cancer cells (16) , ID-1 enhances the invasiveness of tumor cells by inducing the expression of MMP-2 and MMP-9, respectively. The induction of MMP-9 by ID-1 may be through the p65/NF-κB pathway in nasopharyngeal carcinoma cells (17) . In esophageal squamous cell carcinoma (18) , the activation of PI3K/AKT signaling pathway may be involved. These results suggest that the mechanism by which ID-1 induces increased ID-1 levels after 2-ME intervention in BXPC-3 cells. n = 6, mean ± SD, *P < 0.05, **P < 0.01, compared with DMSO group. (C) ID-1 levels after 2-ME intervention in Capan-1 cells. n = 6, mean ± SD, *P < 0.05, compared with DMSO group. (D) ID-1 levels after 2-ME intervention in Capan-2 cells. n = 6, mean ± SD, ***P < 0.001, compared with DMSO group. (E) ID-1 levels after 2-ME intervention in GV254 cells. n = 6, mean ± SD, **P < 0.01, compared with DMSO group. (F) ID-1 levels after 2-ME intervention in Panc-1 cells. n = 6, mean ± SD, *P < 0.05, **P < 0.01, compared with DMSO group. (G) ID-1 levels after 2-ME intervention in SW1990 cells. n = 6, mean ± SD, *P < 0.05, ***P < 0.001, compared with DMSO group. (H) CCK-8 assays to detect cell proliferation ability by 2-ME intervention in SW1990 cells. n = 6, mean ± SD, ***P < 0.001, compared with DMSO group. expression of MMPs may not be unique, and that different mechanisms may exist in different tumor tissues. However, whether these pathways are interrelated and interact with each other remains unknown. VEGF is indeed one of the downstream factors of ID-1. ID-1 may promote tumor angiogenesis by inducing VEGF (19) . However, there is few research on the mechanism of ID-1 induced VEGF expression. Kim et al. (14) reported that ID-1 may induce VEGF expression by regulating HIF-1α, but their results showed that ID-1 did not increase the expression of HIF-1α at the transcriptional level. By preventing the link between HIF-1α and VHL protein, thereby increasing the stability of HIF-1α.
As the endogenous hormone metabolite, 2-ME plays an effective role in antitumor in vivo and in vitro from our data. By 2-ME treatment, ID-1 down-regulation suppressed HIF-1α expression in the SW1990 subcutaneous tumors and liver metastasis tumors in vivo, as well as the tumor sizes, promote the survival rate of mice. By ID1 knockdown, 2-ME showed no additional effect on cell proliferation, wound closure and invasion rate, which indicated the off-target effect of 2-ME on ID1. Previous studies have already demonstrated that 2-ME can disrupt angiogenesis effectively at different stages in the formation of new blood vessels. One important insight in the mechanism of 2-ME on antiangiogenesis is thought to be associated with HIF-1α (20) . The Western blots and histograms showing relative levels of ID-1, HIF-1α, VEGF and MMP-9 subcutaneous tumors between 2-ME and DMSO-treated groups. n = 6, mean ± SD, *P < 0.05, compared with DMSO group. mechanism occurs post-transcriptionally and appears to result from 2-ME induced inhibition of HIF-1α protein synthesis. In a breast cancer mouse model, Huh et al. (11) confirmed that ID-1 level was repressed by 2-ME in tumor and vascular endothelial cells with a dose-effect relationship. According to a Phase I clinical trial, the maximal 2-ME administration dose is 1000 mg/day, and its half-life is 10 h in the human body with a daily dose (21) . In another trial, 2-ME was given from 200 to 1000 mg/day orally and last for 28 days in one circle, and continued for a maximum of six cycles (22) . Based on previous in vivo studies (12, 23, 24) , 2-ME injection at a dose of 100 mg/kg per day was safe and proper for the mice in this study. Although 2-ME did not prevent early stage (2 weeks after modeling) metastasis by MR scan, it might due to the resolution of 3.0T MR. Some small nidus less than 1 mm may be hardly identified by scan. Thus, if there was very small metastasis in the vehicle group, we could not find it in the MR image. Besides, nidus in 2-ME group is all about 1 mm in size, which may reinforce this point of view. So we considered 2-ME 'didn't inhibit', not 'accelerated' the early stage liver metastasis.
According to our findings, local ID-1 expression is correlated with PDAC patients' prognosis even though the log-rank test showed no significance among three survival curves in total. For for BALB/c nu/nu mice in 2-ME and DMSO group 21 days after SW1990 cells liver metastasis modeling. Upper: horizontal view, lower: coronal view, green arrow: hyperintensity nidus. (B) HE staining for livers in 2-ME and DMSO group. Scale bar = 100 µm. (C) Survival curve of mice in 2-ME and DMSO group, P = 0.0349, n = 20 in DMSO group, n = 9 in 2-ME group. (D) Western blots and histograms showing relative levels of ID-1, HIF-1α in metastasis tumors between 2-ME and DMSO-treated groups. n = 6, mean ± SD, *P < 0.05, ***P < 0.001 compared with DMSO group. (E) ID-1 and HIF-1α immunostaining of liver metastasis tumors in 2-ME and DMSO-treated groups.
Scale bar = 100 μm.
the cross curves, analysis should be performed in two stages. In the late stage, the survival curve indicated that patients with low ID-1 score may have a higher rate for long time survival. Although the later stratified analysis revealed patients with medium but not low ID-1 score has a better prognosis than patients with high score, it might be due to the sample size for low score patient (n = 10). All in all, high ID-1 expression could be an independent biomarker associated with poor prognosis in those patients. Based on the results in our study, 2-ME could be a candidate chemotherapeutic agent for PDAC patients.
We present here novel in findings that the role of ID-1 in sw1990 cells behavior. 2-ME treatment reduced the subcutaneous tumor size, and survival rate in SW1990 liver metastasis model, possibly through ID-1 down-regulation. Moreover, the relevance between ID-1 expression and PDAC patients' prognosis is validated. Taken together, these observations indicate that 2-ME treatment may be a potential alternative chemotherapeutic agent for PDAC patients, which still need future clinical investigations.
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